Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses
Cancer Letters · 2026-01 · 638 · 218169
DOI: 10.1016/j.canlet.2025.218169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-01. Verfasst von Kaylee Ermine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Univer…. Hauptthemen laut MEDLINE: Necroptosis, Receptor-Interacting Protein Serine-Threonine Kinases, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Necroptosis, a form of immunogenic cell death (ICD), is frequently impaired in cancer due to the silencing of key regulators, such as RIP3. Despite its potential immunogenic benefits, restoring necroptosis in cancer therapy has been largely underexplored, primarily due to the lack of effective strategies or agents that specifically engage necroptosis without activating apoptosis. In this study, we investigated strategies to restore necroptosis for chemosensitization in RIP3-silenced colorectal cancer (CRC) cells. While reconstituting RIP3 did not impact cell killing by chemotherapy, bypassing RIP3 to induce necroptosis using the natural compound OSW-1 emerged as a promising strategy. OSW-1 displayed strong synergy with 5-fluorouracil (5-FU), effectively eliminating RIP3-silenced CRC cells and tumors through the induction of both necroptosis and apoptosis. Cell death triggered by the OSW-1/5-FU combination was mediated by p53 and CaMKIIδ-driven MLKL phosphorylation, a critical step in the execution of necroptosis. The combination robustly induced ICD hallmarks in CRC cells and immune infiltration in syngeneic tumors. The in vivo antitumor effect of the OSW-1/5-FU combination was largely dependent on antitumor immunity, and abolished by anti-CD8 antibody or immunodeficient hosts. Furthermore, the combination increased immune infiltration in patient-derived primary CRC Air-Liquid Interface (ALI) organoid cultures with autologous immune tumor microenvironment. Collectively, our findings support a novel strategy to activate RIP3-independent necroptosis, providing a compelling rationale to boost the efficacy of chemotherapy via enhanced CRC cell killing and antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Department of Medicine, Keck School of Medicine of University of Southern California (USC), Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, CA, USA.
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department…
- UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Radiation Oncology,…
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
- UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health National Cancer Institute
- Keck School of Medicine of USC
Zitieren
APA
Ermine, K., Chen, D., Hao, S., Liu, Z., Lu, X., Leibowitz, B. J., Wang, P., Jin, Z., Schoen, R. E., Yu, J., & Zhang, L. (2026). Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses. Cancer Letters, 638, 218169. https://doi.org/10.1016/j.canlet.2025.218169
Vancouver
Ermine K, Chen D, Hao S, Liu Z, Lu X, Leibowitz BJ, et al. Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses. Cancer Letters. 2026;638:218169. doi:10.1016/j.canlet.2025.218169
BibTeX
@article{Ermine2026,
author = {Ermine, Kaylee and Chen, Dongshi and Hao, Suisui and Liu, Zhaojin and Lu, Xinyan and Leibowitz, Brian J and Wang, Peng and Jin, Zhendong and Schoen, Robert E and Yu, Jian and Zhang, Lin},
title = {Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses},
journal = {Cancer Letters},
year = {2026},
volume = {638},
pages = {218169},
doi = {10.1016/j.canlet.2025.218169}
}
EUVIMED